What is Lifesci Capital’s Forecast for Immunome Q2 Earnings?

Immunome, Inc. (NASDAQ:IMNM) – Analysts at Lifesci Capital increased their Q2 2026 earnings per share estimates for Immunome in a research report issued to clients and investors on Tuesday, May 12th. Lifesci Capital analyst C. Zhu now expects that the company will post earnings per share of ($0.50) for the quarter, up from their previous estimate of ($0.54). The consensus estimate for Immunome’s current full-year earnings is ($2.50) per share. Lifesci Capital also issued estimates for Immunome’s Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.51) EPS and FY2026 earnings at ($1.99) EPS.

Immunome (NASDAQ:IMNM) last posted its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.12.

Several other equities research analysts also recently weighed in on the company. Truist Financial raised Immunome to a “strong-buy” rating in a report on Monday, May 4th. Wall Street Zen cut shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Immunome in a research report on Wednesday. Wedbush reiterated an “outperform” rating and set a $31.00 price target on shares of Immunome in a research note on Thursday, January 15th. Finally, Craig Hallum raised their price objective on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.45.

Immunome Stock Down 0.8%

NASDAQ:IMNM opened at $22.02 on Friday. The company has a market capitalization of $2.49 billion, a PE ratio of -9.25 and a beta of 2.11. Immunome has a 52-week low of $7.62 and a 52-week high of $27.65. The stock’s 50 day moving average price is $21.99 and its 200 day moving average price is $21.19.

Institutional Trading of Immunome

Hedge funds have recently made changes to their positions in the company. Assetmark Inc. purchased a new stake in shares of Immunome in the third quarter valued at about $39,000. KBC Group NV purchased a new position in Immunome during the first quarter worth about $60,000. BNP Paribas Financial Markets lifted its position in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after purchasing an additional 2,909 shares during the period. Strs Ohio acquired a new stake in Immunome in the fourth quarter valued at about $64,000. Finally, Tower Research Capital LLC TRC boosted its holdings in Immunome by 121.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after purchasing an additional 3,802 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Insider Activity

In other news, Director Philip Wagenheim sold 36,800 shares of the company’s stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $20.47, for a total transaction of $753,296.00. Following the completion of the sale, the director owned 369,347 shares in the company, valued at $7,560,533.09. This represents a 9.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jack Higgins sold 9,438 shares of the stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $21.64, for a total value of $204,238.32. Following the sale, the insider directly owned 22,000 shares of the company’s stock, valued at approximately $476,080. This represents a 30.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 139,438 shares of company stock valued at $2,964,664. Company insiders own 7.21% of the company’s stock.

Immunome News Summary

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $40 price target on Immunome, signaling continued confidence in the company’s longer-term growth prospects. Immunome (NASDAQ:IMNM) Given “Buy” Rating at HC Wainwright
• Positive Sentiment: HC Wainwright improved its earnings outlook for FY2026 and FY2027, while also raising its estimates for Q2, Q3, and Q4 2026, suggesting analysts see a slightly better path to profitability than before.
• Positive Sentiment: Lifesci Capital also raised its FY2026 and Q2/Q3/Q4 2026 EPS estimates, adding to the generally constructive tone around Immunome’s near-term financial trajectory.
• Neutral Sentiment: Lifesci Capital’s FY2027 EPS estimate came in at a slightly improved loss forecast, but the company is still expected to remain unprofitable next year.
• Negative Sentiment: Not all revisions were upbeat: Lifesci Capital trimmed its Q4 2026 EPS estimate slightly, and consensus still points to sizable losses for the year, which may limit near-term upside.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.